tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Whalen HR et al. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime. 2017 Transplantation pmid:26950724
Gralla J and Wiseman AC Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era. 2009 Transplantation pmid:19502965
Morrissey PE Prope tolerance: is it the end or the means? 2009 Transplantation pmid:19502973
Garcia-Criado FJ et al. Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. 1997 Transplantation pmid:9293871
Suzuki H et al. Induction of transplantation tolerance in adult rats by vascularized spleen transplantation. 1997 Transplantation pmid:9293881
Satterthwaite R et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. 1998 Transplantation pmid:9484771
Shin BH et al. Regulation of anti-HLA antibody-dependent natural killer cell activation by immunosuppressive agents. 2014 Transplantation pmid:24342979
Asberg A et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. 2006 Transplantation pmid:16861943
Egawa H et al. FK506 conversion therapy in pediatric liver transplantation. 1994 Transplantation pmid:7513911
Yoon SH et al. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III). 2013 Transplantation pmid:23364483
Yang CW et al. Pharmacological preconditioning with low-dose cyclosporine or FK506 reduces subsequent ischemia/reperfusion injury in rat kidney. 2001 Transplantation pmid:11740384
Benito N et al. Alternariosis after liver transplantation. 2001 Transplantation pmid:11740399
Moxey-Mims MM Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) 1999 Transplantation pmid:10440413
Hodge G et al. Lymphocytic bronchiolitis is associated with inadequate suppression of blood T-cell granzyme B, IFN-gamma, and TNF-alpha. 2010 Transplantation pmid:20559033
Schäffer MR et al. Tacrolimus impairs wound healing: a possible role of decreased nitric oxide synthesis. 1998 Transplantation pmid:9539093
McGhee B et al. Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients. 1997 Transplantation pmid:9326429
Yoshimura N et al. The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. 1994 Transplantation pmid:7517078
Firdaous I et al. Pediatric intravenous FK506--how much are we really infusing? 1994 Transplantation pmid:7517079
Manez R et al. Rejection and hepatitis in liver transplants. 1994 Transplantation pmid:7517080
Ueno P et al. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus. 2017 Transplantation pmid:27490418
Cao W et al. Effects of rapamycin on growth factor-stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fibroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. 1995 Transplantation pmid:7532879
Chaftari AM et al. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation. 2012 Transplantation pmid:22814329
Murase N et al. Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. 1990 Transplantation pmid:1696405
Propper DJ et al. FK506--its influence on anti-class 1 MHC alloantibody responses to blood transfusions. 1990 Transplantation pmid:1696409
Maruyama M et al. Effect of FK506 treatment on allocytolytic T lymphocyte induction in vivo: differential effects of FK506 on L3T4+ and Ly2+ T cells. 1990 Transplantation pmid:1696410
Tuteja S et al. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. 2001 Transplantation pmid:11397967
Kahan BD An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy. 1999 Transplantation pmid:10428260
Washburn K et al. Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. 2001 Transplantation pmid:11726831
Reichenspurner H et al. Optimization of the immunosuppressive protocol after lung transplantation. 1999 Transplantation pmid:10428269
Pilmore HL et al. Tacrolimus for the treatment of gout in renal transplantation: two case reports and review of the literature. 2001 Transplantation pmid:11726837
Soccal PM et al. Improvement of drug-induced chronic renal failure in lung transplantation. 1999 Transplantation pmid:10428288
Lee CM et al. Outcomes in diabetic patients after simultaneous pancreas-kidney versus kidney alone transplantation. 1997 Transplantation pmid:9371670
Ericzon BG et al. The effect of FK506 treatment on pancreaticoduodenal allotransplantation in the primate. 1992 Transplantation pmid:1376501
Ishizuka J et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. 1993 Transplantation pmid:7506454
Dhar DK et al. Effective prevention of ischemic injury of the dearterialized canine liver by FK506 pretreatment. 1993 Transplantation pmid:7506456
Shao X et al. Tacrolimus-associated ischemic optic neuropathy and posterior reversible encephalopathy syndrome after small bowel transplantation. 2012 Transplantation pmid:23128973
Nicolai S and Bunyavanich S Hypersensitivity reaction to intravenous but not oral tacrolimus. 2012 Transplantation pmid:23128975
Tsuchiya T et al. Comparison of pharmacokinetics and pathology for low-dose tacrolimus once-daily and twice-daily in living kidney transplantation: prospective trial in once-daily versus twice-daily tacrolimus. 2013 Transplantation pmid:23792649
Størset E et al. Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study. 2015 Transplantation pmid:25886918
Sharif A et al. Insulin resistance indexes in renal transplant recipients maintained on tacrolimus immunosuppression. 2010 Transplantation pmid:20145524
Kaplan B et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. 1999 Transplantation pmid:10075604
Butani L et al. Amelioration of tacrolimus-induced nephrotoxicity in rats using juniper oil. 2003 Transplantation pmid:12883183
Ciancio G et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. 2011 Transplantation pmid:21107305
Marcén R et al. Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. 2006 Transplantation pmid:16570003
Mor E et al. Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. 1994 Transplantation pmid:7519800
Erden E et al. Plasma FK506 levels in patients with histopathologically documented renal allograft rejection. 1994 Transplantation pmid:7519801
Sood P et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. 2012 Transplantation pmid:23018881
Jain A et al. Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. 2000 Transplantation pmid:10653398
Ciancio G et al. The use of Campath-1H as induction therapy in renal transplantation: preliminary results. 2004 Transplantation pmid:15316372
Hooper DK et al. Risk of tacrolimus toxicity in CYP3A5 nonexpressors treated with intravenous nicardipine after kidney transplantation. 2012 Transplantation pmid:22491658
Sarwal MM et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. 2003 Transplantation pmid:14627912
Ciancio G et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up. 2008 Transplantation pmid:18622280
Bolin P et al. Optimizing tacrolimus therapy in the maintenance of renal allografts: 12-month results. 2008 Transplantation pmid:18622283
Uemura T et al. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. 2011 Transplantation pmid:21841541
Berg UB et al. Renal function before and long after liver transplantation in children. 2001 Transplantation pmid:11544422
Aw MM et al. Calcineurin-inhibitor related nephrotoxicity- reversibility in paediatric liver transplant recipients. 2001 Transplantation pmid:11544444
Murase N et al. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. 1993 Transplantation pmid:7682735
Gruessner RW et al. Mycophenolate mofetil in pancreas transplantation. 1998 Transplantation pmid:9721799
Emond JC et al. Improved results of living-related liver transplantation with routine application in a pediatric program. 1993 Transplantation pmid:7682738
Terakura M et al. Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. 1998 Transplantation pmid:9721804
Kai N et al. Prevention of insulitis and diabetes in nonobese diabetic mice by administration of FK506. 1993 Transplantation pmid:7682740
Woodle ES et al. Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. 1996 Transplantation pmid:8878382
Jacobson PA et al. Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. 2011 Transplantation pmid:21206424
Kershner RP and Fitzsimmons WE Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. 1996 Transplantation pmid:8878385
Richards KR et al. Tacrolimus trough level at discharge predicts acute rejection in moderately sensitized renal transplant recipients. 2014 Transplantation pmid:24784360
Nolan TJ and Schad GA Tacrolimus allows autoinfective development of the parasitic nematode Strongyloides stercoralis. 1996 Transplantation pmid:8878405
Chung BH et al. Suppressive Effect of 1α,25-Dihydroxyvitamin D3 on Th17-Immune Responses in Kidney Transplant Recipients With Tacrolimus-Based Immunosuppression. 2017 Transplantation pmid:28107277
Tanaka A et al. Living related liver transplantation across ABO blood groups. 1994 Transplantation pmid:7522363
Devlin J et al. Nitric oxide generation. A predictive parameter of acute allograft rejection. 1994 Transplantation pmid:7522365
Klupp J et al. Indications of mycophenolate mofetil in liver transplantation. 2005 Transplantation pmid:16286893
Eckhoff DE et al. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. 2000 Transplantation pmid:10830224
Nankivell BJ et al. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras. 2016 Transplantation pmid:27306529
Fukushima D et al. Epstein-Barr virus--associated posttransplantation lymphoproliferative disorder with tacrolimus metabolism deterioration in infants after living-donor liver transplantation. 2015 Transplantation pmid:24846306
Opelz G and Döhler B Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation. 2009 Transplantation pmid:19300179
Rostambeigi N et al. Unique cellular and mitochondrial defects mediate FK506-induced islet β-cell dysfunction. 2011 Transplantation pmid:21200364
Jordan ML et al. Tacrolimus rescue therapy for renal allograft rejection--five-year experience. 1997 Transplantation pmid:9020321
Mazariegos GV et al. Weaning of immunosuppression in liver transplant recipients. 1997 Transplantation pmid:9020325
Marin-Casino M et al. Significant tacrolimus and dronedarone interaction in a kidney transplant recipient. 2014 Transplantation pmid:25243519
Reich DJ et al. Mycophenolate mofetil for renal dysfunction in liver transplant recipients on cyclosporine or tacrolimus: randomized, prospective, multicenter pilot study results. 2005 Transplantation pmid:16003228
Inamura N et al. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. 1988 Transplantation pmid:2447690
Hardinger KL et al. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients. 2005 Transplantation pmid:16003231
Egli A et al. Comparison of the effect of standard and novel immunosuppressive drugs on CMV-specific T-cell cytokine profiling. 2013 Transplantation pmid:23274966
Pascual J et al. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. 2004 Transplantation pmid:15599321
Farley DE et al. The effect of two new immunosuppressive agents, FK506 and didemnin B, in murine pregnancy. 1991 Transplantation pmid:1713360
Vathsala A et al. The immunosuppressive antagonism of low doses of FK506 and cyclosporine. 1991 Transplantation pmid:1713361
Thai NL et al. Alemtuzumab induction and tacrolimus monotherapy in pancreas transplantation: One- and two-year outcomes. 2006 Transplantation pmid:17198247
Hughes JR et al. Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine. 1999 Transplantation pmid:10480422
Cacciarelli TV et al. Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. 1998 Transplantation pmid:9808490
Nakazawa Y et al. Relationship between in vivo FK506 clearance and in vitro 13-demethylation activity in living-related liver transplantation. 1998 Transplantation pmid:9808496
Meiser BM et al. Tacrolimus or cyclosporine: which is the better partner for mycophenolate mofetil in heart transplant recipients? 2004 Transplantation pmid:15446320
Katz IA et al. Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. 1991 Transplantation pmid:1716801
Inomata Y et al. The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation. 1996 Transplantation pmid:8600632
Gruessner RW et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. 1996 Transplantation pmid:8600635
Griffith BP et al. A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation. 1994 Transplantation pmid:7512292
Jordan ML et al. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. 1994 Transplantation pmid:7512293
Yilmaz MI et al. Endothelial functions improve with decrease in asymmetric dimethylarginine (ADMA) levels after renal transplantation. 2005 Transplantation pmid:16378057
Vítko S et al. Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study. 2005 Transplantation pmid:16378069
Vacher-Coponat H et al. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation. 2012 Transplantation pmid:22228415
Zhang W et al. Isoglycyrrhizinate Magnesium Enhances Hepatoprotective Effect of FK506 on Ischemia-Reperfusion Injury Through HMGB1 Inhibition in a Rat Model of Liver Transplantation. 2017 Transplantation pmid:28885495
Guitard J et al. Predictive factors for anemia six and twelve months after orthotopic liver transplantation. 2006 Transplantation pmid:16770241